Efficacy of leukotriene receptor antagonist for erosive esophagitis: A preliminary retrospective comparative study

H. Lee, J. C. Park, S. K. Shin, S. K. Lee, Y. C. Lee

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

While diagnostic overlap exists between gastroesophageal reflux disease and eosinophilic esophagitis especially on histological findings, therapeutic approaches for the two disease entities are very different. Recently, anti-inflammatory treatment, in addition to acid suppressants, has been investigated for gastroesophageal reflux disease. This study investigated whether the incidence of endoscopic erosive esophagitis was lower in recipients of long-term leukotriene receptor antagonist (LTRA) treatment. This retrospective comparative study included 207 recipients of an LTRA and an equal number of controls who underwent screening upper endoscopic examination. Twenty-two (10.6%) and 51 (24.6%) cases of erosive esophagitis were detected in the LTRA and control groups, respectively (P < 0.001). A significantly higher incidence of minimal change esophagitis was also found in the controls compared with the LTRA group (14.5% vs. 2.4%, P < 0.001). On multivariate analysis, LTRA treatment was significantly and inversely associated with erosive esophagitis (odds ratio [OR], 0.25; 95% confidence interval [CI], 0.13 to 0.46). Within the LTRA treatment group, an increased risk of erosive esophagitis was strongly associated with the presence of hiatal hernia (OR, 5.89; 95% CI, 2.20-15.73, P < 0.001) and short duration of LTRA treatment (OR, 0.64; 95% CI, 0.37-0.89, P= 0.022). In conclusion, this preliminary retrospective analysis demonstrated that patients who underwent long-term treatment with a LTRA had low incidence of endoscopic minimal change esophagitis.

Original languageEnglish
Pages (from-to)595-599
Number of pages5
JournalDiseases of the Esophagus
Volume25
Issue number7
DOIs
Publication statusPublished - 2012 Sep 1

Fingerprint

Leukotriene Antagonists
Esophagitis
Retrospective Studies
Odds Ratio
Confidence Intervals
Gastroesophageal Reflux
Therapeutics
Incidence
Eosinophilic Esophagitis
Peptic Esophagitis
Hiatal Hernia
Anti-Inflammatory Agents
Multivariate Analysis
Control Groups
Acids

All Science Journal Classification (ASJC) codes

  • Gastroenterology

Cite this

@article{22af74422d3f444eb7a37b27d6217f58,
title = "Efficacy of leukotriene receptor antagonist for erosive esophagitis: A preliminary retrospective comparative study",
abstract = "While diagnostic overlap exists between gastroesophageal reflux disease and eosinophilic esophagitis especially on histological findings, therapeutic approaches for the two disease entities are very different. Recently, anti-inflammatory treatment, in addition to acid suppressants, has been investigated for gastroesophageal reflux disease. This study investigated whether the incidence of endoscopic erosive esophagitis was lower in recipients of long-term leukotriene receptor antagonist (LTRA) treatment. This retrospective comparative study included 207 recipients of an LTRA and an equal number of controls who underwent screening upper endoscopic examination. Twenty-two (10.6{\%}) and 51 (24.6{\%}) cases of erosive esophagitis were detected in the LTRA and control groups, respectively (P < 0.001). A significantly higher incidence of minimal change esophagitis was also found in the controls compared with the LTRA group (14.5{\%} vs. 2.4{\%}, P < 0.001). On multivariate analysis, LTRA treatment was significantly and inversely associated with erosive esophagitis (odds ratio [OR], 0.25; 95{\%} confidence interval [CI], 0.13 to 0.46). Within the LTRA treatment group, an increased risk of erosive esophagitis was strongly associated with the presence of hiatal hernia (OR, 5.89; 95{\%} CI, 2.20-15.73, P < 0.001) and short duration of LTRA treatment (OR, 0.64; 95{\%} CI, 0.37-0.89, P= 0.022). In conclusion, this preliminary retrospective analysis demonstrated that patients who underwent long-term treatment with a LTRA had low incidence of endoscopic minimal change esophagitis.",
author = "H. Lee and Park, {J. C.} and Shin, {S. K.} and Lee, {S. K.} and Lee, {Y. C.}",
year = "2012",
month = "9",
day = "1",
doi = "10.1111/j.1442-2050.2011.01299.x",
language = "English",
volume = "25",
pages = "595--599",
journal = "Diseases of the Esophagus",
issn = "1120-8694",
publisher = "Wiley-Blackwell",
number = "7",

}

Efficacy of leukotriene receptor antagonist for erosive esophagitis : A preliminary retrospective comparative study. / Lee, H.; Park, J. C.; Shin, S. K.; Lee, S. K.; Lee, Y. C.

In: Diseases of the Esophagus, Vol. 25, No. 7, 01.09.2012, p. 595-599.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Efficacy of leukotriene receptor antagonist for erosive esophagitis

T2 - A preliminary retrospective comparative study

AU - Lee, H.

AU - Park, J. C.

AU - Shin, S. K.

AU - Lee, S. K.

AU - Lee, Y. C.

PY - 2012/9/1

Y1 - 2012/9/1

N2 - While diagnostic overlap exists between gastroesophageal reflux disease and eosinophilic esophagitis especially on histological findings, therapeutic approaches for the two disease entities are very different. Recently, anti-inflammatory treatment, in addition to acid suppressants, has been investigated for gastroesophageal reflux disease. This study investigated whether the incidence of endoscopic erosive esophagitis was lower in recipients of long-term leukotriene receptor antagonist (LTRA) treatment. This retrospective comparative study included 207 recipients of an LTRA and an equal number of controls who underwent screening upper endoscopic examination. Twenty-two (10.6%) and 51 (24.6%) cases of erosive esophagitis were detected in the LTRA and control groups, respectively (P < 0.001). A significantly higher incidence of minimal change esophagitis was also found in the controls compared with the LTRA group (14.5% vs. 2.4%, P < 0.001). On multivariate analysis, LTRA treatment was significantly and inversely associated with erosive esophagitis (odds ratio [OR], 0.25; 95% confidence interval [CI], 0.13 to 0.46). Within the LTRA treatment group, an increased risk of erosive esophagitis was strongly associated with the presence of hiatal hernia (OR, 5.89; 95% CI, 2.20-15.73, P < 0.001) and short duration of LTRA treatment (OR, 0.64; 95% CI, 0.37-0.89, P= 0.022). In conclusion, this preliminary retrospective analysis demonstrated that patients who underwent long-term treatment with a LTRA had low incidence of endoscopic minimal change esophagitis.

AB - While diagnostic overlap exists between gastroesophageal reflux disease and eosinophilic esophagitis especially on histological findings, therapeutic approaches for the two disease entities are very different. Recently, anti-inflammatory treatment, in addition to acid suppressants, has been investigated for gastroesophageal reflux disease. This study investigated whether the incidence of endoscopic erosive esophagitis was lower in recipients of long-term leukotriene receptor antagonist (LTRA) treatment. This retrospective comparative study included 207 recipients of an LTRA and an equal number of controls who underwent screening upper endoscopic examination. Twenty-two (10.6%) and 51 (24.6%) cases of erosive esophagitis were detected in the LTRA and control groups, respectively (P < 0.001). A significantly higher incidence of minimal change esophagitis was also found in the controls compared with the LTRA group (14.5% vs. 2.4%, P < 0.001). On multivariate analysis, LTRA treatment was significantly and inversely associated with erosive esophagitis (odds ratio [OR], 0.25; 95% confidence interval [CI], 0.13 to 0.46). Within the LTRA treatment group, an increased risk of erosive esophagitis was strongly associated with the presence of hiatal hernia (OR, 5.89; 95% CI, 2.20-15.73, P < 0.001) and short duration of LTRA treatment (OR, 0.64; 95% CI, 0.37-0.89, P= 0.022). In conclusion, this preliminary retrospective analysis demonstrated that patients who underwent long-term treatment with a LTRA had low incidence of endoscopic minimal change esophagitis.

UR - http://www.scopus.com/inward/record.url?scp=84866284303&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866284303&partnerID=8YFLogxK

U2 - 10.1111/j.1442-2050.2011.01299.x

DO - 10.1111/j.1442-2050.2011.01299.x

M3 - Article

C2 - 22211520

AN - SCOPUS:84866284303

VL - 25

SP - 595

EP - 599

JO - Diseases of the Esophagus

JF - Diseases of the Esophagus

SN - 1120-8694

IS - 7

ER -